GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (NAS:ASMB) » Definitions » Cyclically Adjusted PS Ratio

Assembly Biosciences (Assembly Biosciences) Cyclically Adjusted PS Ratio : 0.99 (As of May. 05, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Assembly Biosciences Cyclically Adjusted PS Ratio?

As of today (2024-05-05), Assembly Biosciences's current share price is $13.15. Assembly Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $13.31. Assembly Biosciences's Cyclically Adjusted PS Ratio for today is 0.99.

The historical rank and industry rank for Assembly Biosciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

ASMB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.73   Med: 24.08   Max: 45.56
Current: 0.99

During the past years, Assembly Biosciences's highest Cyclically Adjusted PS Ratio was 45.56. The lowest was 0.73. And the median was 24.08.

ASMB's Cyclically Adjusted PS Ratio is ranked better than
85.13% of 511 companies
in the Biotechnology industry
Industry Median: 5.38 vs ASMB: 0.99

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Assembly Biosciences's adjusted revenue per share data for the three months ended in Dec. 2023 was $1.346. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $13.31 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Assembly Biosciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Assembly Biosciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Cyclically Adjusted PS Ratio Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.09 6.03 - - 0.74

Assembly Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.74

Competitive Comparison of Assembly Biosciences's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted PS Ratio falls into.



Assembly Biosciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Assembly Biosciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.15/13.31
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Assembly Biosciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.346/129.4194*129.4194
=1.346

Current CPI (Dec. 2023) = 129.4194.

Assembly Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.475 102.862 0.598
201706 1.633 103.349 2.045
201709 1.838 104.136 2.284
201712 2.092 104.011 2.603
201803 2.114 105.290 2.598
201806 1.880 106.317 2.289
201809 2.068 106.507 2.513
201812 1.758 105.998 2.146
201903 1.816 107.251 2.191
201906 1.436 108.070 1.720
201909 1.960 108.329 2.342
201912 2.061 108.420 2.460
202003 1.396 108.902 1.659
202006 12.669 108.767 15.075
202009 11.697 109.815 13.785
202012 0.348 109.897 0.410
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 1.647 115.734 1.842
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 1.346 129.419 1.346

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assembly Biosciences  (NAS:ASMB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Assembly Biosciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (Assembly Biosciences) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.
Executives
Alexander Schornstein 10 percent owner KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074
Nicole S White officer: Chief Manufacturing Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Gilead Sciences Inc 10 percent owner 333 LAKESIDE DR, FOSTER CITY CA 94404
Jason A Okazaki officer: Chief Legal & Business Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Delaney William E Iv officer: CSO, Virology C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jeanette M Bjorkquist officer: Principal Accounting Officer C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
John G Mchutchison director, officer: CEO and President 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Michael P. Samar officer: See Remarks C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Luisa M Stamm officer: Chief Medical Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032
Michael Houghton director C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Jacqueline Sybil Papkoff officer: See remarks C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032
Gina Consylman director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Richard James Colonno officer: Chief Science Officer ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Thomas Joseph Russo officer: CFO C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032

Assembly Biosciences (Assembly Biosciences) Headlines

From GuruFocus